LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...
Research and Markets has announced the addition of the "Global Factor VIII Deficiency Treatment Market 2017-2021" report to their offering. The report forecasts the global factor VIII market to grow ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved efanesoctocog alfa, a once-weekly treatment for children and adults with hemophilia A. The ...
Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...
For people with hemophilia, deficiencies in factor VIII (hemophilia A) or factor IX (hemophilia B) lead to insufficient thrombin generation, which can lead to excessive or spontaneous bleeding. 3,7 In ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...
Patients with the genetic disorder hemophilia A receive factor VIII protein replacement treatments to replenish this clotting protein in their blood, thus preventing dangerous bleeding. Unfortunately, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results